Drug intelligence / Profile preview

IMGX-101

Development stage: Preclinical
Lead developer: IMGENEX
Modality: Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Parenteral

Overview

IMGX-101 is a therapeutic candidate being developed by IMGENEX for the treatment of hyperlipidemia. It is a biologic agent designed as a single-chain variable fragment (ScFv) or nanobody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9). By binding to and inhibiting PCSK9, IMGX-101 prevents the degradation of low-density lipoprotein receptors (LDLR) on the surface of hepatocytes. This leads to increased LDLR activity, which enhances the clearance of circulating LDL cholesterol from the bloodstream. The drug is currently in the preclinical/discovery stage of development.

Other names: PCSK9 ScFvPCSK-9 ScFvPCSK 9 ScFv

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)

Beyond the preview

Go deeper on IMGX-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMGX-101.

Explore the full profile